These antibodies are validated on HuProt™ Human Protein Microarrays containing over 21,000 full-length human proteins, including the specific target of interest. LEARN MORE
Trial Size Available
Carrier-Free Available
Flow cytometric analysis of PFA-fixed U87 cells. IGFBP3 Mouse Monoclonal Antibody (IGFBP3/3424) followed by goat anti-mouse IgG-CF488 (blue); isotype control (red).
Immunofluorescence analysis of PFA-fixed U87 cells. IGFBP3 Mouse Monoclonal Antibody (IGFBP3/3424) followed by goat anti-mouse IgG-CF488 (green). CF640A phalloidin (red).
Immunofluorescence analysis of PFA-fixed U87 cells. IGFBP3 Mouse Monoclonal Antibody (IGFBP3/3424) followed by goat anti-mouse IgG-CF488 (green). CF640A phalloidin (red).
SDS-PAGE Analysis of Purified IGFBP3 Mouse Monoclonal Antibody(IGFBP3/3424). Confirmation of Purity and Integrity of Antibody.
Western blot analysis of A549 cell lysates using IGFBP3 Mouse Monoclonal Antibody (IGFBP3/3424).
| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol |
|---|---|---|
| Flow Cytometry (Flow) | 1-2ug/million cells | Flow Cytometry Protocol |
| Immunofluorescence (IF) | 1-3ug/ml |
3
0
0
3
3
2
The Insulin-like growth factor-binding proteins, or IGFBPs, are a family of homologous proteins that have co-evolved with the IGFs. They serve not only as shuttle molecules for the soluble IGFs, but also confer a level of regulation to the IGF signaling system. Physical association of the IGFBPs with IGF influences the bio-availability of the growth factors, as well as their concentration and distribution in the extracellular environment. In addition, the IGFBPs appear to have biological activity independent of the IGFs. Seven IGFBPs have thus far been described, each differing in their tissue distribution, half-lives and modulation of IGF interactions with their receptors. IGFBP3 is the most abundant IGFBP and is complexed with roughly 80% of the serum IGFs. Both IGFBP3 and IGFBP4 are released by dermal fibroblasts in response to incision injury.
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time
